- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05557825
The Use of Photobiomodulation in the Management of Radiodermatitis in Head and Neck Cancer Patients
November 10, 2023 updated by: Rebeca Boltes Cecatto, University of Nove de Julho
The Use of Photobiomodulation in the Management of Radiotherapy Side Effects: Case Series of Head and Neck Cancer Patients
It is estimated that there will be 670,000 new cases of cancer worldwide in 2020-2022 and it is known that the most commonly instituted treatments in cancer are chemotherapy, radiotherapy and surgery.
However, these treatments have undesirable side effects, such as Radiodermatitis after Radiotherapy (RD).
In fact, the prevalence of possible side effects after radiotherapy is estimated to be 80 to 90%.
Radiotherapy complications are associated with a negative impact on patients' quality of life and few supportive measures are available for such complications.
Thus, the management of these side effects has been studied in the literature until the present day.
On the other hand, Photobiomodulation (PBM) has an important role in wound repair and tissue regeneration, as it influences the different phases of lesion resolution, including the inflammatory phase, the proliferative phase and the remodeling phase.
Thus, the aim of this study is to report a case series of Head and Neck Cancer Patients diagnosed with radiotherapy-induced acute radiodermatitis treated with PBM and/or PDT.
This is a case series report and the study data will be extracted from the medical records of four head and neck cancer patients with grade 2 to 4 followed up from 2021 at the Laser Therapy Outpatient Clinic in a Universitarian Hospital.
The outcomes are the size of the lesion, the presence of pain assessed by the Visual Analogue Scale (VAS) and the RTOG Scale (Radiation Therapy Oncology Group Scale) to assess the degree of Radiodermatitis before and after PBM/PDT therapy.
Data with positive or negative results will be reported.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
It is estimated that there will be 670,000 new cases of cancer worldwide in 2020-2022 and it is known that the most commonly instituted treatments in cancer are chemotherapy, radiotherapy and surgery.
However, these treatments have undesirable side effects, such as Radiodermatitis after Radiotherapy (RD).
In fact, the prevalence of possible side effects after radiotherapy is estimated to be 80 to 90%.
Radiotherapy complications are associated with a negative impact on patients' quality of life and few supportive measures are available for such complications.
Thus, the management of these side effects has been studied in the literature until the present day.
On the other hand, Photobiomodulation (PBM) has an important role in wound repair and tissue regeneration, as it influences the different phases of lesion resolution, including the inflammatory phase, the proliferative phase and the remodeling phase.
Thus, the aim of this study is to report a case series of Head and Neck Cancer Patients diagnosed with radiotherapy-induced acute radiodermatitis Grade 2 to 4, treated with PBM/PDT.
This is a case series report and the study data will be extracted from the medical records of four head and neck cancer patients with grade 2 to 4 RD followed up from 2021 at the Laser Therapy Outpatient Clinic in a Universitarian Hospital.
The outcomes are the size of the lesion, the presence of pain assessed by the Visual Analogue Scale (VAS) and the RTOG Scale (Radiation Therapy Oncology Group Scale) to assess the degree of Radiodermatitis before and after PBM/PDT therapy.
The assessment will be done pre-treatment, weekly during PBM therapy and post-treatment.
The PBM therapy are focal low-level laser therapy, 1 to 3 Joules per point, depending on the degree of pain, wavelength 630 to 830 nm, transcutaneously on the surface of the tissue injured by radiotherapy, three times a week during radiotherapy treatment and two more applications after the end of radiotherapy Data with positive or negative results will be reported.
Study Type
Observational
Enrollment (Actual)
3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rebeca B Cecatto, M.D. Ph.D.
- Phone Number: +5511970842496
- Email: rebeca.boltes@uni9.pro.br
Study Locations
-
-
-
Sao Paulo, Brazil
- Universidade Nove de Julho / Post-Graduate program Biophotonics Applied to Health Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
outpatient cancer patients undergoing radiotherapy and who show signs of radiodermatitis RTOG II, III or IV
Description
Inclusion Criteria:
- Patients with diagnosis of head or neck cancer
- Must be undergoing Radiotherapy
- Must have a diagnosis of Grade II, III or IV radiodermatitis by RTOG Scale, made during the follow-up of the patient in their routine treatment at the hospital by the oncology team
- who do not present clinical signs of another pathology that justifies the presence of the dermis lesion.
Exclusion Criteria:
- Critical clinical states;
- End-of-life or palliative care;
- Patients with skin lesions of another cause even when undergoing RT;
- Patients referred to the laser clinic for the prevention of radiodermatitis without the active RD lesion.
- Patients who have used another photobiomodulation therapy protocol foresaw injury not related to the study.
- All contraindications already defined in the routine referral to the outpatient clinic (patients who have an active tumor at the site to be irradiated; individuals with a history of photosensitivity to photonic or light therapy;patients who have undiagnosed lesions in the treatment region; patients using topical photosensitizing medications or creams;cognitive, psychiatric or neurological changes that prevent the free understanding of the PBM therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Radiodermatitis Case Group
03 patients with grade 2 to 4 radiodermatitis after radiotherapy for the treatment of head and neck cancer submitted to a PBM/PDT therapy protocol
|
Focal low-level laser therapy, 1 to 3 Joules per point, depending on the degree of pain, wavelength 633 to 830 nm, transcutaneously on the surface of the tissue injured by radiotherapy, three times a week during radiotherapy treatment and two more applications after the end of radiotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity criteria of the Radiation Therapy Oncology Group Scale (RTOG Scale)
Time Frame: Change from Baseline at 14 days after end of radiotherapy treatment
|
RTOG scale assess the degree and intensity of RD.
It identifies degree 0 (no reaction), 1 (faint erythema, dry desquamation, epilation, diminished sweating), 2 (moderate, brisk erythema, exudative dermatitis in plaques and moderate edema), 3 (exudative dermatitis, besides cutaneous folds and intense edema) and 4 (ulceration, hemorrhage, necrosis).
|
Change from Baseline at 14 days after end of radiotherapy treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Analog Scale of Pain
Time Frame: Change from Baseline at 14 days after end of radiotherapy treatment
|
VAS Scale assess the pain intensity.
The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').
|
Change from Baseline at 14 days after end of radiotherapy treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lesion Size
Time Frame: Change from Baseline at 14 days after end of radiotherapy treatment
|
Evaluation of lesion measurement in centimeters
|
Change from Baseline at 14 days after end of radiotherapy treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rebeca B Cecatto, M.D. Ph.D., University of Nove de Julho
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 20, 2023
Primary Completion (Actual)
August 1, 2023
Study Completion (Actual)
August 1, 2023
Study Registration Dates
First Submitted
September 20, 2022
First Submitted That Met QC Criteria
September 23, 2022
First Posted (Actual)
September 28, 2022
Study Record Updates
Last Update Posted (Actual)
November 14, 2023
Last Update Submitted That Met QC Criteria
November 10, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Radiodermatite06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
WepromNeptuneActive, not recruitingMetastatic Colorectal Cancer | Metastatic Head and Neck CancerFrance
Clinical Trials on Photobiomodulation Therapy
-
University of Nove de JulhoMulti Radiance Medical; São José Rugby ClubCompletedRecovery | Performance | High-level Rugby AthletesBrazil
-
Marco Aurélio Vaz, PhDCompletedPerformance | Cyclists | Photobiomodulation TherapyBrazil
-
University of Nove de JulhoWithdrawnPalliative Care | Cancer Patients | Radiotherapy Side Effect | Radiodermatitis; AcuteBrazil
-
University of Nove de JulhoUnknown
-
Quadram Institute BioscienceUniversity of East AngliaNot yet recruitingChronic Fatigue Syndrome | Myalgic Encephalomyelitis
-
University of Sao PauloActive, not recruitingPerformance | Sport | Photobiomodulation | Low Level Laser TherapyBrazil
-
Vita CareTegos S.A.CompletedOsteoarthritis | Osteoarthritis Hand | Osteoarthritis Finger | Osteoarthritis Both HandsBrazil
-
Federal University of Rio Grande do SulAC Camargo Cancer Center; Instituto do Cancer do Estado de São PauloRecruitingMucositis | Xerostomia | HyposalivationBrazil
-
Brooke Army Medical CenterUniformed Services University of the Health Sciences; The Geneva FoundationRecruitingMetatarsal Stress Fracture | Stress Fracture of TibiaUnited States
-
University of BergenUniversidade do Vale do Paraíba; Norwegian Fund for Postgraduate Training in...Completed